The Department of Defense awarded Honeywell (NYSE: HON ) a sizable supply contract Tuesday.
The Defense Logistics Agency, Aviation, extended the term of Honeywell's three-year base contract for the supply of consumable and depot-level reparable spare parts for multiple weapons systems by an additional 18 months. The contract also has three, three-year option periods. One effect of this extension is to add $165.1 million to the�indefinite-delivery requirements contract. Another is to extend the completion date for Honeywell's performance to Nov. 6, 2014.
Weapons systems such as the ones covered in this contract generally accrue to Honeywell's Aerospace division, which at $12 billion in annual business, accounts for roughly $0.32 out of every $1 Honeywell brings in as revenue. As such, Tuesday's contract win could make up close to 1.4% of the Aerospace division's revenues over the next year -- and about 0.4% of Honeywell's overall sales for the year.
Today, the first trading day after the contract was announced, Honeywell shares are up 0.5% as of this writing, trading around $77.30.
Best Electric Utility Companies To Invest In Right Now: Laboratory Corporation of America Holdings(LH)
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company in the United States. The company offers a range of testing services used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease, as well as specialty testing services. Its routine tests include blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, HIV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company?s specialty tests and related services comprise viral load measurements, genotyping and phenotyping, and host genetic factors for managing and treating HIV infections; cytogenetic, molecular cytogenetic, biochemical, and molecular genetic tests for diagnostic genetics; oncology tests for diagnosing and monitoring certain cancers and treatments; clinical trials testing for pharmaceutical companies, which conducts clinical research trials on diag nostic assays; forensic identity testing used in criminal proceedings and parentage evaluation services, as well as testing services in reconstruction cases; allergy testing; and occupational testing for the detection of drug and alcohol abuse. Its customers include independent physicians and physician groups, hospitals, managed care organizations, governmental agencies, employers, pharmaceutical companies, and other independent clinical laboratories. The company operates a network of 51 primary laboratories and approximately 1,700 patient service centers. In addition, it delivers a co-branded electronic health records Lite solution for physician practices. The company works with university, hospital, and academic institutions, such as Duke University, The Johns Hopkins University, the University of Minnesota, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlingto n, North Carolina.
Advisors' Opinion:- [By Monica Wolfe]
Over the past week Chris Davis (Trades, Portfolio) of Davis Selected Advisers added to his holdings in Laboratory Corporation of America (LH).� The guru upped his stake 21.11% by purchasing 1,666,957 shares of the company�� stock.� He bought these shares at an average price of $91.37 per share, and since then the price per share is up about 1% to $92.57 per share.
- [By Johanna Bennett]
LabCorp (LH) climbed 3.2% on an upgrade to Outperform from Underperform by Raymond James.
GoPro (GPRO) rose 5.7% on positive comments from J.P. Morgan analyst Paul Coster ahead of the J.P. Morgan Tech Forum at the 2015 Consumer Electronics Show in Las Vegas on Tuesday.
- [By Seth Jayson]
Laboratory Corp. of America Holdings (NYSE: LH ) reported earnings on July 19. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Laboratory Corp. of America Holdings met expectations on revenues and met expectations on earnings per share. - [By Ben Levisohn]
Any time a stock falls more than 10% in a single day, you know something has gone wrong. Such is the case with medical-testing provider Laboratory Corporation of America (LH), or LabCorp.
Top 10 Logistics Companies To Own In Right Now: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
Advisors' Opinion:- [By Jake L'Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Clovis Oncology(CLVS) posted positive findings from a study of a lung-cancer treatment. The Phase 1 study of the oral treatment, called CO-1686, demonstrated “encouraging” results and progression-free survival in patients, Clovis said. Shares increased 4.2% to $80.75 in recent premarket trading.
- [By Sean Williams]
Clovis Oncology (NASDAQ: CLVS )
Welcome to fantasyland; population: Clovis shareholders! As my Foolish colleague and health care analyst David Williamson pointed out this week, shareholders enjoyed the best possible perk of biotech ownership Monday based on ASCO data -- a daily double. Clovis shares exploded higher as both its Rucaparib study of solid tumors, and CO-1686 for EGFR-mutant non-small-cell lung cancer, demonstrated strong early-stage results. - [By Sean Williams]
Clovis Oncology (NASDAQ: CLVS ) certainly made a name for itself, more than doubling its share price, after reporting positive early stage data on CO-1686 for EGFR-mutant non-small cell lung cancer and rucaparib for solid tumors such as ovarian cancer. Rucaparib provided an 89% clinical benefit to patients with ovarian cancer while CO-1686 indicated a partial response in three out of four patients with the T790M resistance mutation. I would still urge caution among investors, though, as these are still early studies and Clovis lost its then lead drug, CO-101, to a failed mid-stage pancreatic cancer trial in November. �
Top 10 Logistics Companies To Own In Right Now: PACCAR Inc.(PCAR)
PACCAR Inc, together with its subsidiaries, designs, manufactures, and distributes light-, medium-, and heavy-duty trucks and related aftermarket parts worldwide. The company offers its trucks for use in the over-the-road and off-highway hauling of freight, petroleum, wood products, construction, and other materials to independent dealers under the Kenworth, Peterbilt, and DAF nameplates. It also provides finance and leasing products and services, such as inventory financing for independent dealers; and retail loan and lease financing for new and used trucks, as well as other transportation equipment; and full service leasing under the PacLease trade name. In addition, it manufactures and sells industrial winches under the Braden, Carco, and Gearmatic nameplates. PACCAR Inc was founded in 1905 and is headquartered in Bellevue, Washington.
Advisors' Opinion:- [By MONEYMORNING.COM]
In the non-tech part of the portfolio, we're talking about such firms as coffee giant Starbucks Corp. (Nasdaq: SBUX), Baltimore-based mutual fund player T. Rowe Price Group Inc. (Nasdaq: TROW), and Peterbilt truck maker PACCAR Inc (Nasdaq: PCAR).
- [By Lisa Levin]
PACCAR (NASDAQ: PCAR) shares rose 4.88% to $66.89. The volume of PACCAR shares traded was 243% higher than normal. PACCAR shares jumped following word of better-than-expected preliminary orders for a certain truck segment..
- [By Neha Chamaria]
Investors who follow the industrial sector closely should be ready for a busy week ahead, as some of the top names turn up with their quarterly earnings reports. One company to pay attention to is PACCAR (NASDAQ: PCAR ) .
Top 10 Logistics Companies To Own In Right Now: Nortech Systems Incorporated(NSYS)
Nortech Systems Incorporated operates as a contract manufacturing company. It manufactures wire harness cable and printed circuit board assemblies, electronic sub-assemblies, higher level assemblies, and complete devices. The company also provides value added services and technical support, including design, testing, prototyping, and supply chain management; and repair services on circuit boards used in machines in the medical industry. In addition, it engages in the design, manufacture, and post-production service of electronic and electromechanical medical devices for diagnostic, analytical, and other life-science applications. Nortech Systems Incorporated serves various industries that include aerospace and defense; medical; and the industrial markets, which include industrial equipment, transportation, vision, agriculture, and oil and gas. The company markets its products through sales force and independent manufacturers? representatives. Nortech Systems Incorporated was founded in 1981 and is headquartered in Wayzata, Minnesota.
Advisors' Opinion:- [By James E. Brumley]
In a perfect world stocks would move in predictable, manageable ways. We don't live - nor do we trade in - a perfect world. In the real world we have to adapt to and deal with the curve balls the market throws us, and there are no two stocks that illustrate that point better than Document Security Systems, Inc. (NYSEMKT:DSS) and Nortech Systems Incorporated (NASDAQ:NSYS) to today. While both NSYS and DSS are up today, one's overbought and ripe for a pullback, while the other is likely at the beginning of a trade-worthy rally.
Top 10 Logistics Companies To Own In Right Now: Pepsico Inc.(PEP)
PepsiCo, Inc. engages in the manufacture, marketing, and sale of foods, snacks, and carbonated and non-carbonated beverages worldwide. The company operates in four divisions: PepsiCo Americas Foods (PAF); PepsiCo Americas Beverages (PAB); PepsiCo Europe; and PepsiCo Asia, Middle East, and Africa (AMEA). The PAF division offers Lay?s and Ruffles potato chips, Doritos and Tostitos tortilla chips and dips, Cheetos cheese flavored snacks, Fritos corn chips, Quaker Chewy granola bars, and SunChips multigrain snacks in North America; Quaker oatmeal, Aunt Jemima mixes and syrups, Cap?n Crunch cereal, Quaker grits, and Life cereal, as well as Rice-A-Roni, Pasta Roni, and Near East side dishes in North America; and various snack foods under Doritos, Marias Gamesa, Cheetos, Ruffles, Emperador, Saladitas, Sabritas, and Lay?s brands in Latin America. The PAB division provides carbonated soft drinks, beverage concentrates, fountain syrups, and finished goods under Pepsi, Mountain Dew, Gatorade, 7UP, Tropicana Pure Premium, Electropura, Sierra Mist, Epura, and Mirinda brands; ready-to-drink tea, coffee, and water products through joint ventures with Unilever and Starbucks; and sells concentrate to authorized bottlers, and branded finished goods directly to independent distributors and retailers. This division also manufactures third-party brands, such as Dr Pepper, Crush, Rock Star, and Muscle Milk. The PepsiCo Europe division offers Frito Lay Snacks, Pepsi-Cola beverages, Gatorade sports drinks, Tropicana juices, and Quaker foods in Europe. The AMEA division provides snack food under the Lay?s, Kurkure, Chipsy, Doritos, Smith?s, Cheetos, Red Rock Deli, and Ruffles brands; Quaker-brand cereals and snacks; and beverage concentrates, fountain syrups, and finished goods under the Pepsi, Mirinda, 7UP, and Mountain Dew brands. PepsiCo, Inc. was founded in 1898 and is headquartered in Purchase, New York.
Advisors' Opinion:- [By Associated Press]
NEW YORK (AP) -- PepsiCo (NYSE: PEP ) says it plans to start testing a new fountain machine at restaurants that lets people create a variety of flavor combinations, such as strawberry Mountain Dew.
- [By Brian Stoffel]
This was a decision that rival PepsiCo� (NYSE: PEP ) has already made, as it allows the companies to pass on overhead costs to smaller bottlers to provide distribution to stores and gas stations. No timeline was set for the move, but the market clearly thinks that the move will help Coke save money and boost earnings over time.
- [By Maxx Chatsko]
In addition, if the performance of the tobacco industry is any gauge, then soft-drink producers such as Coca-Cola (NYSE: KO ) and PepsiCo (NYSE: PEP ) have little to fear. It's a bit more complicated than tobacco taxes, however. Blaming increased risk of lung cancer on smoking is much more of a slam-dunk than putting all of the blame of rising obesity rates on sugary drinks alone. So it is easy to see why the two companies and the American Beverage Association spent $70 million on lobbying and advertising from 2009 to 2012 to stamp out proposed sugar taxes in 30 states. Still, I think it's only a matter of time before a state sugar tax successfully passes. �
Top 10 Logistics Companies To Own In Right Now: Central Securities Corp (CET)
Central Securities Corporation is a non-diversified, closed-end management investment company. The Company�� primary investment objective is growth of capital. Central Securities Corporation invests primarily in common stocks, but it may invest in bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks and corporations.
The Company, from time to time, invests in securities, the resale of which is restricted. Central Securities Corporation invests in various sectors, including insurance, Semiconductor, Technology Hardware and Equipment, Diversified Industrial, Energy, Software and Services, Banking and Finance and other.
Advisors' Opinion:- [By Joe Eqcome]
Actionable Items:
Highest Positive Spread: ING Emerging Markets High Dividend Equity Fund (IHD)Focus Stock: Central Securities Corporation (CET)Last Week's Focus Stock: Central Securities CorporationJunk Bonds Debacle: The $85 billion monthly bond-purchase program has produced a selloff for "junk" bonds. The U.S. Treasurys jumped 0.18% to 4.39% on Wednesday. The benchmark 10-Year Treasury note has risen 0.5% in the past month.
Top 10 Logistics Companies To Own In Right Now: Chipotle Mexican Grill Inc.(CMG)
Chipotle Mexican Grill, Inc. develops and operates fast-casual, fresh Mexican food restaurants in the United States, Canada, and England. Its restaurants primarily offer burritos, tacos, burrito bowls, and salads. As of December 31, 2011, it operated 1,230 restaurants, which includes 1 ShopHouse Southeast Asian Kitchen. Chipotle Mexican Grill, Inc. was founded in 1993 and is based in Denver, Colorado.
Advisors' Opinion:- [By Laura Brodbeck]
Thursday
Earnings Expected From: United Health Group Incorporated (NYSE: UNH), Mattel, Inc. (NASDAQ: MAT), General Electric Company (NYSE: GE), Fifth Third Bancorp (NASDAQ: FITB), Philip Morris Inc (NYSE: PM), Pepsico, Inc. (NYSE: PEP), Goldman Sachs Group, Inc. (NYSE: GS), Chipotle Mexican Grill, Inc. (NYSE: CMG), American Express Company (NYSE: AXP) Economic Releases Expected: �German PPI, Canadian CPI, Chinese house price dataFriday
No comments:
Post a Comment